GSK Break to the downside coming this week since an hedge order came in for 4/19 exp.
Entry below $40.51
Trade becomes invalid on any gap and go or around the $40.98 area
GSK jemperil clinical trial forecasted to be complete by end of June. It treats endometrial cancer
